title: Hepatotoxicity after a short course of low-dose pyrazinamide.
abstract: We report on a patient who developed extensive centrolobular liver necrosis after a treatment with low-dose (25 mg/kg/d) pyrazinamide for only 4 weeks, combined with rifampicin, 600 mg/d). In the past, the patient already developed severe aminotransferase elevations under isoniazid treatment. After prompt withdrawal of the drugs, a gradual decline of the aminotransferases was observed. No signs of hepatic failure developed. Pyrazinamide has to be used with caution, even in low-dose, especially when combined with rifampicin.
authors.affiliation: Division of Gastroenterology, University of Antwerp (U.I.A.), Belgium.
authors.forename: K A
authors.initials: KA
authors.lastname: al Sarraf
authors.forename: P P
authors.initials: PP
authors.lastname: Michielsen
authors.forename: E I
authors.initials: EI
authors.lastname: Hauben
authors.forename: A
authors.initials: A
authors.lastname: Lefebure
authors.forename: A M
authors.initials: AM
authors.lastname: Ramon
authors.forename: E A
authors.initials: EA
authors.lastname: Van Marck
authors.forename: P A
authors.initials: PA
authors.lastname: Pelckmans
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004359:Drug Therapy, Combination; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects*; D012293:Rifampin / Q000008:administration & dosage
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin